Argenx (ARGX) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Argenx SE, a global immunology company, has announced the outcomes of its Annual General Meeting, where shareholders approved the annual report and accounts for 2023, appointed Dr. Brian L. Kotzin as a new non-executive director, and re-appointed two directors. Shareholders also authorized the Board to issue shares and granted the company permission to amend its articles of association. Notably, one agenda item regarding the remuneration policy did not pass.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.